Blood tests 5 min
MSI and dMMR: what this test means and why it matters
What microsatellite instability (MSI) and mismatch repair deficiency (dMMR) are, how they are tested, how they affect immunotherapy and what they mean for family.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 23 October 2026
MSI (microsatellite instability) and dMMR (mismatch repair deficiency) describe a tumour in which the cell poorly corrects errors made when copying DNA. It is determined on tumour tissue, and the result affects treatment.
How it is tested
- Immunohistochemistry for repair proteins (MLH1, MSH2, MSH6, PMS2): loss of one or more means dMMR.
- PCR or NGS for microsatellite markers: the result is MSI-H (high instability) or MSS (stable).
Why it matters for treatment
- Tumours with dMMR or MSI-H often respond well to immunotherapy (PD-1 and PD-L1 inhibitors). Immunotherapy is used for such tumours including in metastatic colorectal cancer and other sites.
- The result can change therapy choice at earlier stages, for example in colon cancer.
- The test is recommended in colorectal, endometrial and several other cancers.
Link with heredity
Sometimes dMMR is linked to Lynch syndrome, an inherited predisposition. Then a genetics consultation and testing of relatives are recommended.
What to do with the result
- MSI-H / dMMR found. Immunotherapy (PD-1 inhibitors) is discussed: in several tumours it works regardless of organ. The oncologist selects it by type and stage.
- MSS / pMMR. For single-agent immunotherapy this is a less favourable result, but other options remain.
- IHC and PCR results disagree. It happens; the method not yet used is then added.
- Suspected Lynch syndrome. If MSI is found in bowel or uterine cancer, a genetic counsellor for the family is sometimes advised. Take your pathology report and blocks or slides in advance: the test is done on existing material.
What MSI and dMMR are
Cells have a system that repairs DNA errors (mismatch repair, MMR). When it is damaged (dMMR), errors accumulate in repeating DNA stretches: this is called microsatellite instability (MSI-H). Such tumours carry many mutations, so the immune system “sees” them more easily and immunotherapy works better.
The test identifies two states: IHC looks at repair proteins, PCR or NGS at microsatellite repeats. Results usually agree.
In which tumours and why it is checked
MSI is most often found in colorectal and endometrial (uterine body) cancer, less often in stomach cancer and others. In some countries and clinical guidelines the test is recommended in these tumours, and in advanced cancer of other sites it is discussed when further treatment options are needed.
The result matters for two decisions: whether immunotherapy will suit (PD-1 inhibitors are approved for MSI-H tumours regardless of organ) and whether relatives should be checked for Lynch syndrome.
How to prepare and what to ask
- Find out whether the test was done and by which method; if not, ask to add it to the existing pathology.
- Clarify which laboratory did it and whether there is an official report.
- Ask how the result will affect the treatment plan.
- If MSI-H is found, ask about immunotherapy and the criteria for using it.
- If hereditary disease is suspected, ask about genetic counselling. Slide review and extended molecular testing by a second consultant sometimes add this result where it was not done.
How immunotherapy works in MSI-H
Tumours with a repair defect accumulate many mutations and produce many abnormal proteins (neoantigens). The immune system recognises them, but the tumour “switches it off” through the PD-1/PD-L1 signal. PD-1 inhibitors (pembrolizumab, nivolumab, dostarlimab and others) release this brake.
In patients with MSI-H tumours such therapy can give a lasting response, including in advanced disease. Pembrolizumab became the first drug approved by a molecular feature rather than an organ.
What is known about MSI in bowel cancer
In metastatic MSI-H colorectal cancer, first-line immunotherapy often exceeds chemotherapy in duration of control. In early stages (II), MSI-H is linked to a more favourable course and less benefit from fluoropyrimidines alone. In recent years, immunotherapy before surgery in localised MSI-H tumours has been studied, with a very high rate of complete responses.
This is a fast-moving field, so it is important to check current guidance with the oncologist rather than rely on old material.
Side effects and monitoring
Immunotherapy is tolerated differently from chemotherapy and side effects vary: colitis and diarrhoea, pneumonitis, hepatitis, thyroid and adrenal damage, skin reactions. They are rarely but can be serious, and respond better to treatment when found early.
What to do:
- Know the symptoms: diarrhoea, breathlessness, cough, jaundice, severe weakness, rash, headache.
- Report them at once, do not wait for the next visit.
- Have regular tests (liver, thyroid, glucose).
- Tell all doctors that you are on immunotherapy.
- Do not take steroids or immunosuppressants without agreement.
What to ask your doctor
- Has MSI/dMMR testing been done and what was the result?
- Is immunotherapy suitable for me?
- Is a genetics consultation needed?
If you have the test result and it is unclear what it changes, I can go through it with you at a consultation.
Sources
- Agnostic Cancer Therapies (PDQ) — National Cancer Institute
- Pembrolizumab: First Precision Immunotherapy — National Cancer Institute
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
